---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-065826"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-10-14T12:35:20+00:00"
generated_at: "2026-10-14T12:40:06.083331+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Bio, Gilead sign solid-tumor TCE deal: $90M upfront, up to $1.74B milestones

## Summary
- Gilead to pay $90M upfront ($65M cash plus $25M equity at a 30% premium) and up to $45M in near-term preclinical milestones, totaling up to $135M.
- Vir eligible for up to $1.74B in development, regulatory and commercial milestones plus tiered high single-digit to low double-digit royalties on net sales.
- Deal covers three novel PRO-XTEN dual-masked T-cell engager candidates targeting selected solid tumor-associated antigens, with Gilead holding an exclusive license.
- Gilead to buy 1,765,486 VIR shares at $14.16/share (~$25M) under a Stock Purchase Agreement with 1-year standstill, voting and lockup provisions.
- Vir handles discovery, design and optimization; Gilead leads development, manufacturing and commercialization. Vir's second PRO-XTEN collaboration.

## SEC filing metadata
- accession: 0001628280-26-065826
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-10-14T12:35:20+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/0001628280-26-065826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/vir-20261009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-065826
- JSON: https://secwatch.observer/filing/0001628280-26-065826.json
- Plain text: https://secwatch.observer/filing/0001628280-26-065826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.